10-Q · May 11, 2026
MoonLake Immunotherapeutics reported disappointing financial results for Q1 2026, with revenue at $0 and an EPS of -$0.98, missing consensus estimates of -$0.90. Operating expenses surged, largely due to increased R&D…
Earnings analysis · 10-Q
MLTX earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
MoonLake’s Q2 diluted EPS improved to -$0.84 from -$0.98 in Q1 and -$0.87 a year earlier, but the company remained loss-making with a $61.805 million quarterly net loss. Liquidity was substantial at $537.0 million, and…
Read full summary
MoonLake’s Q2 diluted EPS improved to -$0.84 from -$0.98 in Q1 and -$0.87 a year earlier, but the company remained loss-making with a $61.805 million quarterly net loss. Liquidity was substantial at $537.0 million, and management expects funding to reach mid-2028, while $99.5 million of variable-rate debt remains outstanding at 8.45%. The principal incremental risk is potential pharmaceutical tariffs of up to 100%, alongside pending securities litigation and ongoing dependence on capital to fund operations.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.84
What stood out
-
Quarterly Loss Narrowed
Q2 diluted EPS was -$0.84, improving from -$0.98 in Q1 2026 and -$0.87 in Q2 2025. The company nevertheless reported a quarterly net loss of $61.805 million.
-
Cash Runway Extends to Mid-2028
Cash, cash equivalents and short-term marketable securities totaled $537.0 million at June 30, 2026, supporting management’s expected operating runway to mid-2028.
-
Debt Maturity Remains Long-Dated
The company had $99.5 million of variable-rate debt outstanding as of June 30, 2026. The loans bear interest at 8.45% and mature in April 2030.
-
Debt Facility Flexibility Increased
The August 3, 2026 loan amendment increased the permitted debt basket for cash-secured letter-of-credit reimbursement obligations from $1.0 million to $3.0 million and increased the landlord-waiver threshold from $1.0 million to $3.5 million.
-
Controls Rated Effective
Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026, following implementation of a new ERP system in May 2026.
What to watch
-
Potential Pharmaceutical Tariffs
The filing introduces explicit exposure to pharmaceutical tariffs of up to 100% on covered imports, beginning July 31, 2026, although implementation and exemptions remain uncertain. Such tariffs could increase clinical, manufacturing and supply-chain costs.
-
Securities Litigation Remains Pending
The Peters Action amended complaint was filed on April 16, 2026, and defendants moved to dismiss on June 16, 2026; the motion remains pending. The company cannot estimate any reasonably possible loss or range of loss.
-
Variable-Rate Debt Exposure
The company had $99.5 million of variable-rate debt outstanding at an interest rate of 8.45% as of June 30, 2026. Although management states a hypothetical 100-basis-point rate change would not have had a material effect, higher rates could increase future cash interest expense.
-
ERP Control Transition Risk
The new ERP system implemented in May 2026 automated, modified or newly designed certain internal controls over financial reporting. Although controls were deemed effective, transition-related execution or control deficiencies remain a monitoring risk.
-
Continued Operating Losses
The company remains loss-making, with Q2 diluted EPS of -$0.84 and a quarterly net loss of $61.805 million. Continued operating losses increase dependence on the reported $537.0 million liquidity balance and future financing or partnership proceeds.
Management's outlook
Management expects existing capital to fund operating expenses and capital expenditures to mid-2028. Cash, cash equivalents and short-term marketable securities totaled $537.0 million at June 30, 2026; no revenue or EPS guidance was provided.
Earlier filings 4
10-K · February 25, 2026
MoonLake Immunotherapeutics reported a significant increase in operating expenses for the year ended December 31, 2025, with a net loss of $230.3 million, up from $121.2 million in 2024. The company has not generated…
10-Q · November 5, 2025
MoonLake Immunotherapeutics reported a disappointing Q3 2025, continuing its trend of losses with no generated revenue. The operating loss reached $71.4 million while the diluted EPS declined to -1.1, missing estimates…
10-Q · August 5, 2025
MoonLake Immunotherapeutics reported a significant increase in operating expenses and net losses for Q2 2025 compared to the previous year, with no revenue generated. Management anticipates sustained operational…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.